Two identical phase 3 studies have shown that 5% imiquimod cream is efficacious and safe for the treatment of typically sized (≤2.0 cm) superficial basal cell carcinomas (sBCCs).1 While most sBCCs are this size, a proportion are larger (≥2 cm).2,3 This study sought to determine if imiquimod would also be efficacious and safe for the treatment of larger sBCC.
Shumack S, Gebauer K, Quirk C, Macdonald K, Walters S, Owens M. 5% Imiquimod Cream for the Treatment of Large Superficial Basal Cell Carcinoma. Arch Dermatol. 2004;140(10):1286–1287. doi:10.1001/archderm.140.10.1286
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: